期刊文献+

探讨间质性肺疾病的临床特征

Investigate the Clinical Features of Interstitial Lung Disease
下载PDF
导出
摘要 目的探讨间质性肺疾病患者的临床病征特点和肺功能情况,为临床治疗提供参考依据。方法我院对80例间质性肺疾病患者进行研究分析,根据诊断分成IPF组和非IPF组,对患者的临床症状、体征、肺功能情况进行了统计分析。结果 IPF组有45例咳嗽患者,31例呼吸困难患者,22例杵状指,12例爆裂音,非IPF组患者以上症状病例数分别是35例,24例,18例,6例,两组患者病症类型数据差异存在统计学意义(P<0.05),IPF组爆裂音,柞状指的患者更多,差异有统计学意义(P<0.05)。结论按照患者的症状、体征、肺功能等特点,可以进行临床间质性肺疾病的诊断,IPF和非IPF都有其特点,不同的特点可以作为临床诊断的依据,让临床治疗更加具有针对性,提升临床治疗效果。 Objective To investigate the clinical features and pulmonary function of patients with interstitial lung disease, and to provide reference for clinical treatment. Methods 80 cases of patients with interstitial lung disease in our hospital to diagnostic analysis, divided into IPF group and non IPF group of patients with clinical symptoms, signs, pulmonary function were analyzed. Results IPF group had 45 cases of patients with cough, dyspnea in 31 cases of patients, 22 cases of clubbing, 12 cases of crackles, non IPF patients above symptoms cases were 35 cases, 24 cases, 18 cases, 6 cases, statistical differences between two groups of patients with the disease type of data (P 〈 0.05), IPF group crackles, tussah finger more patients, the difference was statistically significant (P 〈 0.05). Conclusion According to the characteristics of symptoms and signs, pulmonary function, which can be used for clinical diagnosis of interstitial lung disease, IPF and non IPF has its own characteristics, different characteristics can be used as a clinical diagnosis, more targeted for clinical treatment, improve the clinical treatment effect.
作者 胡晓丽
出处 《中国卫生标准管理》 2017年第8期58-60,共3页 China Health Standard Management
关键词 间质性肺疾病 临床表现 肺功能 interstitial lung disease clinical manifestation pulmonary function
  • 相关文献

参考文献7

二级参考文献60

  • 1宋淑菊,段婷.以肺间质纤维化为首发表现的皮肌炎合并骨梗死1例[J].中国实用内科杂志,2006,26(3):390-391. 被引量:3
  • 2段报喜,黄润月,储永良.细胞因子治疗特发性肺纤维化[J].中国组织工程研究与临床康复,2007,11(10):1940-1942. 被引量:9
  • 3Beretta L, Caronni M, Raimondi M, et al. Oral cyclophosphamide improves pulmonary function in ~clerodenna patients with fibrosing alveolitis: experience in one centre [ J ]. Clin Rheumatol, 2007,26 (2) :168-172.
  • 4Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease [ J ]. N Engl J Med, 2006,354(25) :2655-2666.
  • 5Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease [ J ]. J Rheumatol, 1991,18(10) :1520-1528.
  • 6Jones PW, Quirk FH, Baveystock CM, et al. The St George's Re- spiratory Questionnaire[J]. Respir Med, 1991,85 ( Suppl B) :25- 31.
  • 7Ware JE Jr, Sherboume CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection [ J ]. Med Care, 1992,30(6) :473-483.
  • 8ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test[J]. Am J Respir Crit Care Med, 2002,166 ( 1 ) : 111- 117.
  • 9Kim EA, Johkoh T, Lee KS, et al. Interstitial pneumonia in pro- gressive systemic sclerosis: serial high-resolution CT findings with functional correlation[J]. J Comput Assist Tomogr, 2001,25 (5) : 757-763.
  • 10Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant in- terstitial lung disease in limited scleroderma: histopathology, clini- cal features, and survival[ J]. Chest, 2008,134 (3) :601-605.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部